百奥文图斯

最新新闻

• 评级变动
  J.P. Morgan Sticks to Their Hold Rating for Bioventus (BVS)
  TipRanks · 2025/5/7
• 评级变动
  TR | OpenAI - 4o Maintains Bioventus(BVS.US) With Hold Rating, Raises Target Price to $8
  \u5e02\u573a\u8d44\u8baf · 2025/8/24
• 评级变动
  Craig-Hallum Maintains Bioventus(BVS.US) With Buy Rating, Announces Target Price $17
  \u5e02\u573a\u8d44\u8baf · 2025/3/13
• 评级变动
  Analysts Have Conflicting Sentiments on These Healthcare Companies: Atai Beckley N.V. (ATAI), Bioventus (BVS) and Crinetics Pharmaceuticals (CRNX)
  TipRanks · 2026/7/7
• 评级变动
  CJS Securities Initiates Bioventus(BVS.US) With Buy Rating, Announces Target Price $14
  \u5e02\u573a\u8d44\u8baf · 2026/3/27
• 评级变动
  Cantor Fitzgerald Maintains Bioventus(BVS.US) With Buy Rating, Raises Target Price to $14
  \u5e02\u573a\u8d44\u8baf · 2025/8/11
• 评级变动
  CCORF Maintains Bioventus(BVS.US) With Buy Rating, Maintains Target Price $15
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• 评级变动
  Craig-Hallum Maintains Bioventus(BVS.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/5/24
• 评级变动
  Cantor Fitzgerald Initiates Bioventus(BVS.US) With Buy Rating, Announces Target Price $12
  \u5e02\u573a\u8d44\u8baf · 2025/7/8
• 评级变动
  Bravura Solutions Cut to Neutral From Outperform by Macquarie BVS.AU
  Dow Jones · 2025/8/14
• Craig-Hallum Maintains Bioventus(BVS.US) With Buy Rating, Announces Target Price $16
  \u5e02\u573a\u8d44\u8baf · 2026/7/7
• Earnings Flash (BVS) Bioventus Inc. Posts Q2 Adjusted EPS $0.22 per Share, Vs. FactSet Est of $0.22
  MT Newswires · 2026/8/5
• 评级变动
  J.P. Morgan Keeps Their Hold Rating on Bravura Solutions Limited (BVS)
  TipRanks · 2026/8/17
• 评级变动
  CCORF Initiates Bioventus(BVS.US) With Buy Rating, Announces Target Price $19
  \u5e02\u573a\u8d44\u8baf · 2026/8/17
• Craig-Hallum Maintains Bioventus(BVS.US) With Buy Rating, Raises Target Price to $18
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• 评级变动
  Craig-Hallum Maintains Bioventus(BVS.US) With Buy Rating, Announces Target Price $15
  \u5e02\u573a\u8d44\u8baf · 2025/8/7
• 评级变动
  Barrington Maintains Bioventus(BVS.US) With Buy Rating, Raises Target Price to $14
  \u5e02\u573a\u8d44\u8baf · 2026/3/6
• Barrington Maintains Bioventus(BVS.US) With Buy Rating, Maintains Target Price $14
  \u5e02\u573a\u8d44\u8baf · 2026/7/6
• 评级变动
  Barrington Initiates Bioventus(BVS.US) With Buy Rating, Announces Target Price $13
  \u5e02\u573a\u8d44\u8baf · 2026/2/9
• Barrington Maintains Bioventus(BVS.US) With Buy Rating, Raises Target Price to $18
  \u5e02\u573a\u8d44\u8baf · 2026/8/6

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。